John V Heymach Selected Research

John V Heymach Research Topics

Disease

176	Neoplasms (Cancer) 11/2022 - 09/2004
126	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 03/2006
67	Lung Neoplasms (Lung Cancer) 08/2022 - 06/2004
25	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2012
21	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 06/2004
20	Adenocarcinoma of Lung 05/2022 - 10/2006
11	Hypoxia (Hypoxemia) 01/2021 - 02/2007
11	Disease Progression 01/2021 - 05/2009
11	Squamous Cell Carcinoma of Head and Neck 01/2021 - 06/2010
9	Carcinogenesis 01/2021 - 01/2012
7	Adenocarcinoma 03/2021 - 07/2015
6	Melanoma (Melanoma, Malignant) 01/2022 - 04/2010
6	Breast Neoplasms (Breast Cancer) 12/2018 - 12/2008
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 10/2017
5	Brain Neoplasms (Brain Tumor) 01/2021 - 06/2008
5	Exanthema (Rash) 01/2020 - 07/2010
4	Malignant Mesothelioma 10/2020 - 06/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 04/2011
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 05/2009
3	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 07/2011
3	COVID-19 11/2021 - 01/2021
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 09/2004
3	Carcinoma (Carcinomatosis) 01/2020 - 10/2006
3	Ovarian Neoplasms (Ovarian Cancer) 04/2017 - 01/2007
3	Leukemia 01/2017 - 05/2012
3	Colorectal Neoplasms (Colorectal Cancer) 01/2013 - 01/2010
2	Sepsis (Septicemia) 01/2022 - 02/2018
2	Lymphoma (Lymphomas) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

32	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2007
28	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2008
23	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 05/2005
21	ErbB Receptors (EGF Receptor)IBA 12/2021 - 07/2006
18	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2016
16	Pharmaceutical PreparationsIBA 01/2021 - 01/2005
15	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2006
15	vandetanib (ZD6474)IBA 04/2016 - 07/2006
13	Tyrosine Kinase InhibitorsIBA 01/2021 - 05/2007
12	CytokinesIBA 01/2022 - 01/2010
12	Phosphotransferases (Kinase)IBA 01/2021 - 12/2007
11	LigandsIBA 01/2021 - 09/2012
11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2016
11	Angiogenesis InhibitorsIBA 10/2019 - 09/2004
10	Bevacizumab (Avastin)FDA Link 01/2021 - 03/2006
9	Biological ProductsIBA 01/2020 - 01/2005
9	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2012
9	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2007
8	PlatinumIBA 01/2022 - 08/2011
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 02/2007
8	RNA (Ribonucleic Acid)IBA 10/2021 - 02/2016
8	Circulating Tumor DNAIBA 01/2021 - 03/2016
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2012 - 09/2004
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2022 - 10/2017
7	Gefitinib (Iressa)FDA Link 05/2009 - 07/2006
6	Messenger RNA (mRNA)IBA 01/2020 - 05/2008
6	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 11/2008
5	HM781-36BIBA 11/2022 - 10/2019
5	AntigensIBA 01/2022 - 05/2014
5	Peptides (Polypeptides)IBA 01/2022 - 03/2014
5	B7-H1 AntigenIBA 01/2021 - 02/2016
5	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2007
5	Carboplatin (JM8)FDA LinkGeneric 12/2013 - 11/2008
4	AntibodiesIBA 01/2022 - 04/2011
4	NucleotidesIBA 01/2022 - 08/2013
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 11/2013
4	Sorafenib (BAY 43-9006)FDA Link 10/2016 - 06/2011
4	Cetuximab (Erbitux)FDA Link 12/2013 - 07/2006
3	NivolumabIBA 11/2022 - 01/2018
3	IpilimumabIBA 11/2022 - 12/2019
3	osimertinibIBA 01/2022 - 12/2018
3	InterleukinsIBA 01/2022 - 03/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 09/2012
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2012
3	Transcription Factors (Transcription Factor)IBA 01/2021 - 08/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2021 - 03/2010
3	pembrolizumabIBA 10/2020 - 01/2020
3	Small Interfering RNA (siRNA)IBA 01/2020 - 04/2017
3	ChemokinesIBA 01/2020 - 07/2011
3	Protons (Proton)IBA 01/2020 - 01/2017
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 08/2013
3	cediranib (AZD2171)IBA 10/2019 - 08/2007
3	MicroRNAs (MicroRNA)IBA 01/2019 - 08/2014
3	EnzymesIBA 01/2019 - 01/2010
3	pazopanib FDA Link 01/2018 - 03/2010
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 09/2008
3	Sunitinib (Sutent)FDA Link 11/2012 - 05/2007
3	afliberceptIBA 11/2011 - 12/2008
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2011 - 01/2005
2	trametinibIBA 01/2022 - 01/2020
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2015
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2017
2	durvalumabIBA 01/2022 - 01/2022
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2021 - 06/2010

Therapy/Procedure

85	Therapeutics 08/2022 - 01/2005
37	Drug Therapy (Chemotherapy) 11/2022 - 06/2004
37	Radiotherapy 01/2022 - 04/2011
22	Immunotherapy 08/2022 - 01/2016
6	Neoadjuvant Therapy 01/2022 - 01/2018
4	Aftercare (After-Treatment) 01/2021 - 09/2016
3	Chemoradiotherapy 01/2022 - 01/2013
3	Proton Therapy 01/2021 - 01/2018